Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 12/20 | 0.64 |
| ▸ | PDE3A | Q14432 | 12/20 | 0.64 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.64 |
| ▸ | MAOA | P21397 | 1/20 | 0.64 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.64 |
| ▸ | F10 | P00742 | 1/20 | 0.56 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.51 |
| ▸ | PDE4A | P27815 | 2/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.50 |
| ▸ | GALR3 | O60755 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7322526 | 0.99 | PDE3B (0.63) | PDE3BPDE3AABCB11MAOAADORA2A | |
| SCHEMBL8264681 | 0.91 | PDE3B (0.77) | PDE3BPDE3AABCB11MAOAADORA2A | |
| SCHEMBL10769306 | 0.90 | PDE3B (0.60) | PDE3BPDE3AABCB11MAOAADORA2A | |
| Hydrochloric Acid SCHEMBL11290551 | 0.90 | PDE3B (0.76) | PDE3BPDE3AABCB11MAOAADORA2A | |
| SCHEMBL9781454 | 0.89 | PDE3B (0.64) | PDE3BPDE3AABCB11MAOAADORA2A | |
| SCHEMBL7712293 | 0.88 | PDE3B (0.61) | PDE3BPDE3AABCB11MAOAADORA2A | |
| Pimobendan SCHEMBL1997246 | 0.87 | PDE3B (0.81) | PDE3BPDE3AABCB11MAOAADORA2A | |
| Pimobendan SCHEMBL2466855 | 0.87 | PDE3B (0.84) | PDE3BPDE3AABCB11MAOAADORA2A | |
| Pimobendan SCHEMBL27623 | 0.87 | PDE3B (0.84) | PDE3BPDE3AABCB11MAOAADORA2A | |
| Pimobendan SCHEMBL29386190 | 0.87 | PDE3B (0.84) | PDE3BPDE3AABCB11MAOAADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6110471-A | ADMINISTERING PHOSPHODIESTERASE FOR INHIBITION OF THE CYCLES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2000-08-29 | — | — | US | claimed |
| EP-0330052-B1 | Use of benzimidazoles for preparing a medicine with an anti-ischemial activity on the heart, and combinations with betablockers or bradycardics | THOMAE GMBH DR K (DE) | 1993-12-15 | — | — | EP | claimed |
| US-20120264605-A1 | Multi-Functional Ionic Liquid Compositions for Overcoming Polymorphism and Imparting Improved Properties for Active Pharmaceutical, Biological, Nutritional, and Energetic Ingredients | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2012-10-18 | — | — | US | disclosed |
| EP-0330052-B1 | Use of benzimidazoles for preparing a medicine with an anti-ischemial activity on the heart, and combinations with betablockers or bradycardics | THOMAE GMBH DR K (DE) | 1993-12-15 | — | — | EP | disclosed |
| EP-0387762-A2 | Medicament with positive inotropic activity, containing a synergistically active mixture consisting of a benzimidazole and a beta-blocker, its preparation and use | Dr. Karl Thomae GmbH (DE) | 1990-09-19 | — | — | EP | disclosed |
| EP-0330052-A2 | Use of benzimidazoles for preparing a medicine with an anti-ischemial activity on the heart, and combinations with betablockers or bradycardics | Dr. Karl Thomae GmbH (DE) | 1989-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264605-A1 | Multi-Functional Ionic Liquid Compositions for Overcoming Polymorphism and Imparting Improved Properties for Active Pharmaceutical, Biological, Nutritional, and Energetic Ingredients | SLC5A6, PNLIP, IPMK | PDE3B 451/4885PDE3A 677/4885ABCB11 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.